These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Reversing anticoagulation in the hemorrhaging patient. Treml B; Oswald E; Schenk B Curr Opin Anaesthesiol; 2019 Apr; 32(2):206-212. PubMed ID: 30817397 [TBL] [Abstract][Full Text] [Related]
10. Clinical trials of new anticoagulants. Anderson J; O'Donnell M Vnitr Lek; 2006 Mar; 52 Suppl 1():123-6. PubMed ID: 16637460 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. Lauw MN; Coppens M; Eikelboom JW Can J Cardiol; 2014 Apr; 30(4):381-4. PubMed ID: 24680169 [TBL] [Abstract][Full Text] [Related]
12. [Influence of fibrinolysis inhibitors on anticoagulant induced hemorrhages]. Vogel G; Klöcking HP Folia Haematol Int Mag Klin Morphol Blutforsch; 1973; 99(4):367-75. PubMed ID: 4127132 [No Abstract] [Full Text] [Related]
13. [Hemorrhagic complications during warfarin treatment]. Gumulec J; Kessler P; Penka M; Klodová D; Králová S; Brejcha M; Wróbel M; Sumná E; Blatný J; Klaricová K; Riedlová P; Lasota Z Vnitr Lek; 2006 Mar; 52 Suppl 1():79-91. PubMed ID: 16637455 [TBL] [Abstract][Full Text] [Related]
14. [Challenges of the antithrombotic treatment. The Danish Society for Thrombosis and Hemostasis]. Münster AM; Kristensen SR; Ugeskr Laeger; 2008 Mar; 170(12):1055. PubMed ID: 18397673 [No Abstract] [Full Text] [Related]
15. Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Rothman MT Nat Clin Pract Cardiovasc Med; 2005 Sep; 2(9):465-74. PubMed ID: 16265587 [TBL] [Abstract][Full Text] [Related]
16. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210 [TBL] [Abstract][Full Text] [Related]
17. [Haemo-cholecyst as a complication of anticoagulant and anti-platelet treatment]. Ángel JM; Bermúdez RP; Conde MA; Sampedro JE; Jofré JG Cir Esp; 2011 May; 89(5):327-9. PubMed ID: 21419396 [No Abstract] [Full Text] [Related]
18. Prevention and treatment of major blood loss. Szabo S; Oikonomopoulos T; Hoffmeister HM N Engl J Med; 2007 Sep; 357(12):1260; author reply 1261. PubMed ID: 17881761 [No Abstract] [Full Text] [Related]
19. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904 [TBL] [Abstract][Full Text] [Related]
20. [Routine use of fibrinolysis inhibitors in obstetrics?]. Loch EG Med Klin; 1967 Jan; 62(2):57-9. PubMed ID: 5301899 [No Abstract] [Full Text] [Related] [Next] [New Search]